Charles River Laboratories' stock surge reflects strong financial results, governance changes, and strategic growth initiatives, boosting investor confidence.
J&J reports durability data for bladder cancer 'pretzel' drug TAR-200, showing a 72.7% complete response rate and sustained benefits after FDA filing.